* Meta-terms correspond to biological or medical specialty concerned with one or more keywords (or keywords hierarchies), qualifiers, or resource types. Other terms also benefit from this structure, when the topic warrants it, eg education. See the list.

Doc'CISMeF search for this specility :


Preferred Label : oncology;

True Meta (CISMeF) : O;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/thalidomide
2024
false
false
false
France
French
risk management
thalidomide
teratogens
abnormalities, drug-induced
pregnancy
thalidomide
guideline
forms
patient education handout
continuity of patient care
Neuropathy peripheral
thromboembolism
Drug-Related side effects and adverse reactions
pregnancy tests
contraception
package leaflet

---
http://publications.msss.gouv.qc.ca/msss/document-000288/
2024
false
false
false
Canada
patient education handout
screening for cancer
Program
breast neoplasms
Breast cancer
breast cancer
cancer screening
early detection of cancer

---
https://www.santepubliquefrance.fr/regions/antilles/documents/enquetes-etudes/2024/survie-des-personnes-atteintes-de-cancer-en-guadeloupe-2008-2018
2024
France
technical report
People
guadeloupe
neoplasm, malignant
cancer
neoplasms
persons
Cancer Survivorship Research
disease
survival

---
https://www.santepubliquefrance.fr/regions/antilles/documents/enquetes-etudes/2024/survie-des-personnes-atteintes-de-cancer-en-martinique-2008-2018
2024
France
technical report
survival
disease
neoplasm, malignant
People
cancer
persons
martinique
neoplasms
Cancer Survivorship Research

---
https://www.santepubliquefrance.fr/regions/ocean-indien/documents/enquetes-etudes/2024/survie-des-personnes-atteintes-de-cancer-a-la-reunion-2008-2018
2024
France
technical report
cancer
survival
Cancer Survivorship Research
People
disease
neoplasm, malignant
group processes
persons
Meeting
neoplasms
Reunion

---
https://www.has-sante.fr/jcms/p_3415645/fr/qinlock-ripretinib-tumeurs-stromales-gastro-intestinales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Advanced Gastrointestinal Stromal Tumor
Refractory Malignant Gastrointestinal Stromal Tumor
antineoplastic agents
ripretinib
administration, oral
evaluation of the transparency committee
gastrointestinal stromal tumors
ripretinib

---
https://www.has-sante.fr/jcms/p_3498747/fr/radelumin-18f-psma-1007-cancer-de-la-prostate
2024
false
false
false
France
radiopharmaceuticals
insurance, health, reimbursement
Positron-Emission tomography
neoplasm staging
Prostate-Specific antigen
PSMA-1007 (18F)
evaluation of the transparency committee
prostatic neoplasms
PSMA-1007
Fluorine-18

---
https://www.has-sante.fr/jcms/p_3468175/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2024
false
false
false
France
Cisplatin/Durvalumab/Gemcitabine Regimen
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
cisplatin
Gemcitabine
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
durvalumab
adult
guidelines for drug use
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
durvalumab

---
https://www.has-sante.fr/jcms/p_3498750/fr/keytruda-pembrolizumab-carcinome-a-cellules-renales
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
clear cell renal cell carcinoma
Lenvatinib/Pembrolizumab Regimen
Advanced Clear Cell Renal Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
pembrolizumab
evaluation of the transparency committee
pembrolizumab
carcinoma, renal cell

---
https://www.santepubliquefrance.fr/presse/2024/premiere-etude-partenariale-sur-la-survie-des-personnes-atteintes-de-cancer-a-la-reunion-entre-2008-et-2018
https://www.santepubliquefrance.fr/regions/ocean-indien/documents/enquetes-etudes/2024/survie-des-personnes-atteintes-de-cancer-a-la-reunion-2008-2018
2024
France
technical report
Reunion
group processes
persons
Meeting
data collection
On Study
cancer
Clinical Study
Cancer Survivorship Research
People
survival
neoplasm, malignant
Off Study
DICOM Study
neoplasms
disease

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/protocole-medical-national-initier-un-test-immunochimique-de-recherche-de-sang-occulte-dans-les-selles-ou-une-coloscopie-a-des-fins-de-depistage-ou-de-diagnostic-du-cancer-colorectal.html
2024
Canada
public health guidelines
Test Name
immunochemistry
colonoscopy
On Study
screening for cancer
dermatomyositis
Colorectal Cancer
Cancer Diagnosis
biomedical research
Laboratory Procedure
Screening Colonoscopy
Test Dosing Unit
Screening for Colorectal Cancer
cancer screening
malignant neoplasm colon/rectum
early detection of cancer
Initiation
diagnosis
no diagnosis
Fecal Occult Blood Test
Blood Products Laboratory Testing
feces
screening for occult blood in feces
Clinical Study Protocol
medical research
colorectal neoplasms
occult blood

---
https://www.ema.europa.eu/en/medicines/human/EPAR/herwenda
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab
Trastuzumab
trastuzumab
biosimilar pharmaceuticals

---
https://www.ethique-cancer.fr/avis/avis-ndeg44-note-signalement
2024
France
public health guidelines
What Month is it
After-Hours care
Moral
Electronic Nicotine Delivery Systems
neoplasm, malignant
ethics, clinical
ethics
Care
Malignant Neoplasm
How True Feel Carefree Right Now
neoplasms
Healthcare Activity
cancer
Healthcare
Permanent

---
https://www.has-sante.fr/jcms/p_3501630/fr/tepkinly-epcoritamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
France
evaluation of the transparency committee
Murine Large Cell
Gastric Diffuse Adenocarcinoma
lymphoma, diffuse
B-Lymphocyte
lymphoma, large B-Cell, diffuse
Epcoritamab
b-lymphocytes
b lymphocyte
malignant lymphoma, nos
Childhood Lymphoma
Murine B-Lymphocytes
cells
Adult Lymphoma

---
https://www.inrs.fr/media.html?refINRS=AC%20184
2024
France
journal article
Exhibition
neoplasm, malignant
cancer
Cancer Risk
Exposure Domain
europe
risk factor
Survey
risk factors
risk factor for malignancy
Exposure
Inquiry
neoplasms
occupational neoplasms
effects of exposure to external cause, nos
data collection
No Risk Factors
detective
Occupational Malignant Neoplasm
Investigation
occupational exposure

---
https://cngof.fr/app/pdf/FICHES%20D'INFORMATION%20DES%20PATIENTES/Gyn%C3%A9cologie//FICHE%20INFO%20-%20Chirurgie%20de%20la%20glande%20de%20bartholin%20-%202024%20.pdf
2024
France
patient education handout
Ablation Therapy
bartholin's glands
Limburgish Language
abscess of bartholin's gland
Surgical Procedure
cysts
Abnormal Cells to Leukocytes Ratio Measurement
Bartholin Gland Cyst
EDNRB wt Allele
operative procedure, nos
cyst of bartholin's gland
Abscess
Overdenture
excision, nos
Surgical Procedure was Curative Therapy
general surgery
abscess

---
https://cngof.fr/app/pdf/FICHES%20D'INFORMATION%20DES%20PATIENTES/Gyn%C3%A9cologie//FICHE%20INFO%20-%20Curages%20ganglionnaires%20-%202024.pdf
2024
France
patient education handout
Sentinel Lymph Node
Pelvis
Limburgish Language
Overdenture
pelvis, nos
operative procedure, nos
general surgery
Sentinel Lymph Node
lymph node excision
Pelvic
ganglia
Surgical Procedure was Curative Therapy
Murine Sentinel Lymph Node
Surgical Procedure

---
https://minerva-ebp.be/FR/Article/2367
2024
Belgium
critical appraisal or critical reading
Exercise Pain Management
Periodic Acid Schiff Staining Method
chemical element, nos
elements
STEPS to Enhance Physical Activity
physical exercise, nos
Efficacy Study
fatigue
fatigue
systolic pressure
neoplasm, malignant
Study Element
Cancer Fatigue
SLC22A18 wt Allele
Pulmonary Artery Intimal Sarcoma
Element
efficiency
Scaffold Attachment Factor B1
Platelets Additive Solution
Premorbid Adjustment Scale
During Exercise
cancer
exercise
neoplasms
Step Unit of Distance

---
https://www.has-sante.fr/jcms/p_3505636/fr/rybrevant-amivantamab-cancer-bronchique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
carboplatin
amivantamab
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
EGFR Exon 20 Insertion Mutation
Pemetrexed
adult
package leaflet
summary of product characteristics
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
bronchial neoplasms
amivantamab-vmjw

---
https://www.has-sante.fr/jcms/p_3505761/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
bronchial neoplasms
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
selpercatinib
package leaflet
summary of product characteristics
guidelines for drug use
advanced RET fusion-positive non-small cell lung cancer
RET Fusion Positive
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-11-03-2024-sur-le-medicament-keytruda-dans-le-cadre-dune-demande-daap
2024
false
false
false
France
French
treatment outcome
pembrolizumab
Antineoplastic Agents, Immunological
drug information
Resectable Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
neoplasm recurrence, local
risk
pembrolizumab

---
https://ansm.sante.fr/tableau-acces-derogatoire/blenrep
2024
false
false
false
France
French
infusions, intravenous
drug information
antibodies, monoclonal, humanized
belantamab mafodotin
Antineoplastic Agents, Immunological

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/depistage-cancer-uterus-recommandations.html
2024
Canada
public health guidelines
early detection of cancer
Cervical Carcinoma
implantation in uterus, nos
Implantation Method of Administration
Detection
Test Dosing Unit
papillomaviridae
Human Papillomavirus Viruses
Cervical Cancer pT1a1 TNM Finding v8
Primary
cancer screening
uterine cervical neoplasms
prostheses and implants
Blood Products Laboratory Testing
Prior Primary
Test Name
dermatomyositis
malignant neoplasm cervix
screening for cancer
Administration via Implantation
Human Papillomavirus
Cervical Cancer Screening
Biological Detection Test
quebec
Altretamine/Etoposide/Procarbazine
human papillomavirus, nos
cancer of the uterine cervix
principal
Primary Cause of Death
detective
health planning guidelines
Implantation

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/equivalence-du-seuil-de-positivite-des-tests-immunochimiques-de-recherche-de-sang-occulte-dans-les-selles-pour-le-depistage-du-cancer-colorectal.html
2024
Canada
review of literature
feces
early detection of cancer
Equivalent
screening for occult blood in feces
cancer screening
screening for cancer
Research
Search
research
immunochemistry
Blood in Stool
colorectal neoplasms
Occult Blood Measurement
Colorectal Cancer
Screening for Colorectal Cancer
occult blood
Liquid Tumor
malignant neoplasm colon/rectum

---
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child

---
https://kce.fgov.be/fr/publications/tous-les-rapports/depistage-du-cancer-du-poumon-chez-les-personnes-a-haut-risque
2024
Belgium
technical report
risk assessment
persons
cancer screening
lung cancer
risk
Screening for Lung Cancer
People
High-Risk Cancer
screening for cancer
early detection of cancer
lung neoplasms

---
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate

---
https://ansm.sante.fr/disponibilites-des-produits-de-sante/medicaments/novantrone-10-mg-5-ml-solution-a-diluer-pour-perfusion-mitoxantrone-chlorhydrate-de
2024
false
false
false
France
French
drug information
mitoxantrone hydrochloride
mitoxantrone

---
https://www.has-sante.fr/jcms/p_3487097/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
evaluation of the transparency committee
glofitamab

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3471037/fr/
2024
France
health technology assessment
genome, nos
Early Stage Breast Carcinoma
breast cancer
Useful
hospitals, proprietary
Clinical Data
Signature
Genome
early
Clinical Lot
breast neoplasms
Ambulatory Care Facility
neoplasm staging
genomics
Clinical Batch
genome
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3487181/fr/optune
2024
France
health technology assessment
antimitotic agents
electric field
Antimitotic Agent
NovoTTF-100A Device
family characteristics
Data Field
ARID1A wt Allele
Electricity
generations
In the Field
Generator Dosing Unit
Generator Device
Scope
Generator

---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab

---
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib

---
https://www.has-sante.fr/jcms/p_3487169/fr/tagrisso-osimertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bronchial neoplasms
administration, oral
antineoplastic agents
osimertinib
adult
evaluation of the transparency committee
carcinoma, non-small-cell lung
osimertinib

---
https://www.has-sante.fr/jcms/p_3488409/fr/libtayo-cemiplimab-cancer-bronchopulmonaire-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
adult
platinum compounds
PD-L1 Positive
evaluation of the transparency committee
carcinoma, non-small-cell lung
cemiplimab

---
https://www.has-sante.fr/jcms/p_3488415/fr/jemperli-dostarlimab-cancer-de-l-endometre
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
adult
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
evaluation of the transparency committee
endometrial neoplasms
dostarlimab

---
https://www.has-sante.fr/jcms/p_3490834/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
sacituzumab govitecan
HER2/Neu Negative
Hormone Receptor Positive
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan

---
https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information Document
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety Information
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
pregnant women
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida

---
https://www.calameo.com/onco-occitanie/read/0071780925791d9acadba?language=fr&page=1
2024
France
scientific and technical information
cancer
neoplasms
Pregnant
pregnancy, nos
neoplasm, malignant
Occupational Malignant Neoplasm
pregnancy
Pregnancy
occupational neoplasms

---
https://www.calameo.com/onco-occitanie/read/007178092848008cacc48?language=fr&page=1
2024
France
patient education handout
neoplasms
has patient
pregnancy, nos
Pregnancy
Pregnant
neoplasm, malignant
Cancer Patient
pregnancy
patients
cancer

---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib

---
https://ansm.sante.fr/tableau-marr/methotrexate-per-os
2024
false
false
false
France
French
guidelines for drug use
risk management
methotrexate
administration, oral
patient education handout
medication errors

---
https://www.academie-medecine.fr/face-au-cout-eleve-des-nouveaux-traitements-medicaux-en-cancerologie/
2024
France
scientific and technical information
Medically Treated Reflux
FANCE wt Allele
medical oncology
Comprehensive Score for Financial Toxicity
New Lesion Identification
health care costs
face
Costs
Murine Face
treatment costs
Face
Newar Language
Face

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Emprunter-apres-un-cancer
2024
France
patient education handout
During or After
neoplasms
neoplasm, malignant
Malignant Neoplasm
cancer
Status Post

---
http://beh.santepubliquefrance.fr/beh/2024/5/2024_5_1.html
2024
France
journal article
Convenient
france
French Language
Program
french
Screening for Colorectal Cancer
organization
cancer screening
Schedule
malignant neoplasm colon/rectum
screening for cancer
early detection of cancer
French Catheter Gauge
Organization
Participation
Respect
Scheduled
Colorectal Cancer
Version
appraiser
colorectal neoplasms
mass screening
Estimate
Statistical Estimation

---
http://beh.santepubliquefrance.fr/beh/2024/5/2024_5_2.html
2024
France
journal article
malignant neoplasm cervix
Program
Cervical Carcinoma
cancer of the uterine cervix
organization
National Cancer Program
screening for cancer
Convenient
Electronic System Deployment
cancer screening
Cervical Cancer Screening
mass screening
french
Cervical Cancer pT1a1 TNM Finding v8
early detection of cancer
uterine cervical neoplasms
What Month is it
france
CHFR Gene
Organization

---
https://www.has-sante.fr/jcms/p_3498143/fr/penumbra-ace
2024
France
health technology assessment
carcinoembryonic antigen
Catheter
Cyclophosphamide/Doxorubicin
Cisplatin/Cytarabine/Etoposide
pulmonary aspiration, nos
Angiotensin Converting Enzyme Measurement
Catheter Device
carcinoembryonic antigen
catheter, nos
Aspiration, CTCAE
catheterization
Aspiration
Angiotensin-Converting Enzyme
ACE Gene
suction
Respiratory Tract Aspiration

---
https://www.santepubliquefrance.fr/regions/antilles/documents/enquetes-etudes/2024/survie-des-personnes-atteintes-de-cancer-dans-les-departements-et-regions-d-outre-mer.-2008-2018.-materiel-et-methodes
2024
France
technical report
oceans and seas
Cancer Survivorship Research
SEA Mouse
protestantism
persons
GPER1 wt Allele
Departure
neoplasms
Repeat Unit
Staphylococcal Enterotoxin A
MERTK wt Allele
methods and instrumentation
Diagnostic, Therapeutic, or Research Equipment
cancer
People
Technique
neoplasm, malignant
survival
disease
G-Protein Coupled Estrogen Receptor 1

---
https://ansm.sante.fr/tableau-acces-derogatoire/rybrevant
2024
false
false
false
France
French
summary of product characteristics
amivantamab-vmjw
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
guidelines for drug use
package leaflet

---
https://ansm.sante.fr/tableau-marr/etanercept-1
2024
false
false
false
France
French
risk management
Etanercept
patients guideline
drug information
Drug-Related side effects and adverse reactions

---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab

---
https://www.has-sante.fr/jcms/p_3412521/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://www.has-sante.fr/jcms/p_3412521/en/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
idecabtagene vicleucel
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
idecabtagene vicleucel
multiple myeloma

---
https://ansm.sante.fr/tableau-acces-derogatoire/tecartus-0-4-2-x-108-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
brexucabtagene autoleucel
drug information
Refractory B Acute Lymphoblastic Leukemia
precursor cell lymphoblastic Leukemia-Lymphoma
brexucabtagene autoleucel
gene therapy

---
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet

---
https://ansm.sante.fr/tableau-acces-derogatoire/keytruda-25-mg-ml-solution-a-diluer-pour-perfusion#
2024
false
false
false
France
French
drug information
triple negative breast neoplasms
pembrolizumab
pembrolizumab
summary of product characteristics
package leaflet
guidelines for drug use
adult
Early Stage Triple-Negative Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
inflammatory breast neoplasms
Antineoplastic Agents, Immunological
endometrial neoplasms
clear cell renal cell carcinoma
renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions

---
https://ansm.sante.fr/tableau-marr/teclistamab
2024
false
false
false
France
French
popular works
drug information
Teclistamab
risk management
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/adcetris-50-mg-poudre-pour-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
continuity of patient care
guideline
hodgkin disease
child
adolescent
adult
antineoplastic combined chemotherapy protocols
brentuximab vedotin
Brentuximab Vedotin
infusions, intravenous

---
https://ansm.sante.fr/tableau-marr/venetoclax
2024
false
false
false
France
French
risk management
venetoclax
venetoclax
patient education handout
tumor lysis syndrome
administration, oral
antineoplastic agents

---
https://ansm.sante.fr/tableau-marr/panobinostat
2024
false
false
false
France
French
risk management
Panobinostat
panobinostat
administration, oral
medication errors
patients guideline
patient compliance

---
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy

---
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2024
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
drug information
selpercatinib
pyrazoles
pyridines

---
https://cancer.be/cancer/le-cancer/
2024
false
false
false
Belgium
neoplasms
neoplasms
neoplasms
neoplasms
popular works

---
https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19

---
https://ansm.sante.fr/tableau-marr/lenalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
lenalidomide
multiple myeloma
lymphoma, mantle-cell
teratogens
continuity of patient care
drug monitoring
clinical chemistry tests
myelodysplastic syndromes
guidelines for drug use
popular works
venous thromboembolism
Tumor Flare Reaction
neoplasms
Chemical and Drug Induced Liver Injury
angiogenesis inhibitors
angiogenesis inhibitors
thalidomide
thalidomide
thalidomide
Lenalidomide
Lenalidomide

---
https://ansm.sante.fr/tableau-marr/pomalidomide
2024
false
false
false
France
French
risk management
pregnancy
contraception
teratogens
abnormalities, drug-induced
multiple myeloma
pomalidomide
continuity of patient care
Drug-Related side effects and adverse reactions
risk factors
guidelines for drug use
thrombocytopenia
neutropenia
blood cell count
thromboembolism
Infections
patient education handout
pregnancy tests
forms
thalidomide
thalidomide

---
https://www.has-sante.fr/jcms/p_3418058/fr/imjudo-tremelimumab-carcinome-hepato-cellulaire
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
tremelimumab
antineoplastic agents
antineoplastic combined chemotherapy protocols
durvalumab
adult
Advanced Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
Durvalumab/Tremelimumab Regimen
evaluation of the transparency committee
carcinoma, hepatocellular
tremelimumab

---
https://www.has-sante.fr/jcms/p_3418037/fr/imfinzi-durvalumab-carcinome-hepato-cellulaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
tremelimumab
durvalumab
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
infusions, intravenous
evaluation of the transparency committee
durvalumab
carcinoma, hepatocellular

---
https://www.has-sante.fr/jcms/p_3417971/fr/opdivo-nivolumab-adenocarcinome-gastrique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Advanced Gastric Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
adenocarcinoma of esophagus
esophageal neoplasms
Advanced Esophageal Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
HER2/Neu Negative
PD-L1 Positive
infusions, intravenous
nivolumab
evaluation of the transparency committee
adenocarcinoma
Nivolumab
stomach neoplasms

---
https://www.academie-medecine.fr/intelligence-artificielle-et-cancer/
2023
France
journal article
cancer
neoplasm, malignant
neoplasms
Artificial intelligence
intelligence, nos
artificial intelligence
Cancer

---
https://www.academie-medecine.fr/la-voie-de-signalisation-de-sting-dans-les-lymphocytes-t-applications-potentielles-en-immunotherapie-anticancereuse/
2023
France
journal article
t-lymphocytes
Immunotherapy
t lymphocyte
immunotherapy
attention
Applications
Applications
antineoplastic agents
Applications
immunotherapy, nos

---
https://www.anses.fr/fr/content/pas-reutiliser-traverses-chemin-de-fer-creosote
2023
false
false
false
France
French
creosote
vigilance note
carcinogens
carcinogens, environmental

---
https://ansm.sante.fr/tableau-marr/idecabtagene-vicleucel
2023
false
false
false
France
French
guidelines for drug use
popular works
risk management
idecabtagene vicleucel
idecabtagene vicleucel
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
drug compounding
idecabtagene vicleucel
gene therapy
immunotherapy, adoptive
idecabtagene vicleucel
continuity of patient care
nervous system diseases
infusions, intravenous
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
Cytokine Release Syndrome
Cytokine Release Syndrome
signs and symptoms

---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2023
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel

---
https://www.has-sante.fr/jcms/p_3419164/fr/tecartus-brexucabtagene-autoleucel-cellules-auto-logues-cd3-transduites-anti-cd19-leucemie-aigue-lymphoblastique-lal
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
recurrence
adult
brexucabtagene autoleucel
infusions, intravenous
immunotherapy, adoptive
Recurrent B Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
evaluation of the transparency committee
brexucabtagene autoleucel
precursor b-cell lymphoblastic leukemia-lymphoma

---
https://www.has-sante.fr/jcms/p_3420695/fr/lenvima-lenvatinib-cancer-de-l-endometre
2023
false
false
false
France
antineoplastic agents
protein kinase inhibitors
lenvatinib
antineoplastic combined chemotherapy protocols
pembrolizumab
Lenvatinib/Pembrolizumab Regimen
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Refractory Endometrial Carcinoma
Unresectable Endometrial Carcinoma
administration, oral
evaluation of the transparency committee
lenvatinib
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3419176/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-et-lymphome-de-haut-grade-a-cellules-b-lhgcb
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
axicabtagene ciloleucel
axicabtagene ciloleucel
infusions, intravenous
Recurrent Diffuse Large B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
adult

---
https://www.has-sante.fr/jcms/p_3148278/fr/evaluation-de-la-performance-et-de-la-place-de-la-mammographie-par-tomosynthese-dans-le-programme-national-de-depistage-organise-du-cancer-du-sein-volet-2
2023
France
public health guidelines
cancer screening
mass screening
Organization
breast neoplasms
Breast cancer
mammography
screening mammography
breast cancer
program evaluation
screening for cancer
Organization
organization
early detection of cancer

---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2023
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive

---
https://ansm.sante.fr/tableau-acces-derogatoire/breyanzi
2023
false
false
false
France
French
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
summary of product characteristics
package leaflet
guidelines for drug use
lymphoma, large B-Cell, diffuse
adult
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
continuity of patient care
immunotherapy, adoptive
antigens, CD19
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/teclistamab
2023
false
false
false
France
French
drug information
Teclistamab
adult
multiple myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
summary of product characteristics
package leaflet
antibodies, monoclonal
Antineoplastic Agents, Immunological
teclistamab

---
https://ansm.sante.fr/tableau-acces-derogatoire/enhertu-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
summary of product characteristics
package leaflet
guidelines for drug use
Metastatic Gastric Adenocarcinoma
stomach neoplasms
adenocarcinoma
neoplasm metastasis
Locally Advanced Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Locally Advanced Gastroesophageal Junction Adenocarcinoma
HER2/Neu Positive
trastuzumab deruxtecan
infusions, intravenous
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
Metastatic HER2-Positive Breast Carcinoma
Unresectable HER2-Positive Breast Carcinoma
Refractory HER2-Positive Breast Carcinoma
HER2-Low Breast Carcinoma
Metastatic HER2-Low Breast Carcinoma
neoplasm recurrence, local

---
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular

---
https://ansm.sante.fr/tableau-acces-derogatoire/lynparza-100-mg-et-150-mg-comprimes-pellicules
2023
false
false
false
France
French
drug information
olaparib
administration, oral
olaparib
breast neoplasms
HER2-Negative Breast Carcinoma

---
https://ansm.sante.fr/tableau-marr/daratumumab
2023
false
false
false
France
French
guideline
patient education handout
risk management
daratumumab
daratumumab
Laboratory test related to immunohematology (procedure)
Laboratory test interference
immunologic tests
hematologic tests

---
https://ansm.sante.fr/tableau-marr/ciltacabtagene-autoleucel
2023
false
false
false
France
French
risk management
guidelines for drug use
patient education handout
Ciltacabtagene Autoleucel
infusions, intravenous
immunotherapy, adoptive
Product containing genetically modified T-cell (product)
Receptors, Chimeric Antigen
Cytokine Release Syndrome
continuity of patient care
Ciltacabtagene Autoleucel
neurotoxicity syndromes
drug compounding
ciltacabtagene autoleucel

---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2023
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy

---
https://ansm.sante.fr/tableau-marr/brexucabtagene-autoleucel
2023
false
false
false
France
French
risk management
brexucabtagene autoleucel
genetic therapy
gene therapy
Cytokine Release Syndrome
signs and symptoms
guidelines for drug use
patient education handout
Drug-Related side effects and adverse reactions
nervous system diseases
brexucabtagene autoleucel
brexucabtagene autoleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2023
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease

---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2023
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care

---
https://www.has-sante.fr/jcms/p_3348751/fr/carvykti-ciltacabtagene-autoleucel-myelome-multiple
2023
false
false
false
France
Ciltacabtagene Autoleucel
Ciltacabtagene Autoleucel
treatment outcome
insurance, health, reimbursement
adult
recurrence
immunotherapy, adoptive
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
package leaflet
summary of product characteristics
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
ciltacabtagene autoleucel
evaluation of the transparency committee
multiple myeloma

---
https://ansm.sante.fr/tableau-atu-rtu/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7

---
https://ansm.sante.fr/tableau-marr/propranolol
2023
false
false
false
France
French
risk management
propranolol
propranolol hydrochloride
administration, oral
guidelines for drug use
patients guideline
child
Drug-Related side effects and adverse reactions
bronchial spasm
hypoglycemia
convulsive seizures
adrenergic beta-antagonists
hemangioma, capillary
propranolol

---
https://ansm.sante.fr/tableau-marr/fentanyl-5
2023
false
false
false
France
French
administration, sublingual
fentanyl
analgesics, opioid
risk management
narcotics
guidelines for drug use
patients guideline
fentanyl
Sublingual Tablet Dosage Form

---
https://ansm.sante.fr/tableau-atu-rtu/venclyxto-10-mg-50mg-100-mg-comprimes-pellicules
2023
false
false
false
France
French
venetoclax
venetoclax
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
leukemia, myeloid, acute
precursor cell lymphoblastic Leukemia-Lymphoma
Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
leukemia, lymphocytic, chronic, B-Cell
drug information
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic
sulfonamides
Bridged Bicyclo Compounds, Heterocyclic

---
https://www.snfge.org/tncd/cancer-colorectal-metastatique
2023
false
false
France
French
colonic neoplasms
neoplasm metastasis
colonic neoplasms
signs and symptoms
liver neoplasms
liver neoplasms
hepatectomy
liver neoplasms
neoplasm metastasis
lung neoplasms
palliative care
neoplasm metastasis
clinical trials as topic
continuity of patient care
antineoplastic protocols
colonic neoplasms
antibodies, monoclonal
antibodies, monoclonal
antineoplastic agents
antineoplastic agents
iatrogenic disease
hypertension
skin diseases
hypertension
prognosis
practice guideline

---
https://www.cochrane.org/fr/CD007930/GYNAECA_les-medicaments-qui-restreignent-la-croissance-des-nouveaux-vaisseaux-sanguins-inhibiteurs-de
2023
false
true
false
France
United Kingdom
treatment outcome
meta-analysis
french abstract
angiogenesis inhibitors
ovarian neoplasms

---
https://www.snfge.org/tncd/cancer-voies-biliaires
2023
false
false
false
France
French
biliary tract neoplasms
biliary tract neoplasms
biliary tract neoplasms
biliary tract neoplasms
antineoplastic agents
practice guideline

---
http://publications.msss.gouv.qc.ca/msss/document-002124/
2023
false
false
false
Canada
French
antineoplastic agents
infusions, intravenous
safety management
neoplasms
injections, intravenous
drug compounding
quebec
antineoplastic agents
guideline
nurses, male
professional role
infusions, intravenous
injections, intravenous
Infusion Pumps
extravasation of diagnostic and therapeutic materials
antineoplastic agents
protective clothing
occupational exposure
patient safety
catheterization, central venous

---
https://ansm.sante.fr/tableau-marr/lutecium-177lu-oxodotreotide
2023
false
false
false
France
French
lutetium Lu 177 dotatate
risk management
patients guideline
lutetium Lu 177 dotatate
infusions, intravenous
radiotherapy
radiopharmaceuticals
radiopharmaceuticals
neuroendocrine tumors
lutetium (177Lu) oxodotreotide
drug information
organometallic compounds
octreotide
octreotide
organometallic compounds
octreotide

---
https://ansm.sante.fr/tableau-marr/rituximab
2023
false
false
false
France
French
risk management
Rituximab
Rituximab
infusions, intravenous
injections, subcutaneous
rituximab
guidelines for drug use
risk
leukoencephalopathy, progressive multifocal
Infections
Drug-Related side effects and adverse reactions
continuity of patient care
drug monitoring
patient education handout
drug compounding

---
https://ansm.sante.fr/tableau-marr/rituximab-1
2023
false
false
false
France
French
Rituximab
Rituximab
risk management
infusions, intravenous
rituximab
medication errors
guidelines for drug use
patient education handout
risk
leukoencephalopathy, progressive multifocal
Infections
Drug-Related side effects and adverse reactions
continuity of patient care
drug monitoring

---
https://ansm.sante.fr/tableau-marr/rituximab-2
2023
false
false
false
France
French
Rituximab
Rituximab
risk management
Drug-Related side effects and adverse reactions
patient education handout
guidelines for drug use
infusions, intravenous
rituximab
leukoencephalopathy, progressive multifocal
Infections
medication errors
continuity of patient care

---
https://www.cochrane.org/fr/CD012299/SYMPT_des-doses-elevees-de-medicaments-opioides-pour-la-prise-en-charge-de-la-douleur-chronique-non
2023
United Kingdom
review of literature
french abstract
chronic pain
pain management
chronic pain
Cancer Pain
back pain
opiate agonist, nos
drug, nos
opioids
analgesics, opioid

---
https://www.cochrane.org/fr/CD013448/GYNAECA_interventions-en-matiere-dexercice-physique-pour-les-adultes-atteints-dun-cancer-et-recevant-une
2023
United Kingdom
review of literature
french abstract
radiotherapy
antineoplastic agents
Physics
Cancer
physical exercise, nos
Adult
disease
radiation therapy, nos
exercise
neoplasms
neoplasm, malignant
Adult
cancer
adult
Antineoplastic agents
adulthood

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/impact-de-lactivite-physique-sur-les-effets-indesirables-associes-au-cancer-et-aux-traitements-oncologiques-chez-ladulte.html
2023
Canada
review of literature
adulthood
Associated treatments
neoplasms, second primary
adult
physics
Cancer
Physics
Adult
neoplasm, malignant
Adult
Combined treatment
Associated treatments
Oncology
cancer
exercise
Oncologists

---
https://www.has-sante.fr/jcms/p_3430191/fr/libtayo-cemiplimab-cancer-du-col-de-l-uterus
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
cemiplimab
infusions, intravenous
Antineoplastic Agents, Immunological
Metastatic Cervical Carcinoma
Recurrent Cervical Carcinoma
Refractory Cervical Carcinoma
evaluation of the transparency committee
cemiplimab
uterine cervical neoplasms

---
https://www.has-sante.fr/jcms/p_3430182/fr/rybrevant-amivantamab-cancer-bronchique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
amivantamab
advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
carcinoma, non-small-cell lung
Activating EGFR Exon 20 Mutation
evaluation of the transparency committee
amivantamab-vmjw
carcinoma, non-small-cell lung

---
https://www.has-sante.fr/jcms/p_3428422/fr/locametz-gozetotide-cancer-de-la-prostate
2023
false
false
false
France
insurance, health, reimbursement
Gozetotide
Radiopharmaceutical Preparation Kit Dosage Form
gallium (68Ga) gozetotide
radiopharmaceuticals
gallium 68 PSMA-11
adult
Positron-Emission tomography
FOLH1 protein, human
evaluation of the transparency committee
prostatic neoplasms

---
https://www.has-sante.fr/jcms/p_3430422/fr/mabthera-rituximab-pemphigus-vulgaris-pv-modere-a-severe
2023
false
false
false
France
infusions, intravenous
treatment outcome
insurance, health, reimbursement
rituximab
pemphigus vulgaris
adult
immunologic factors
drug therapy, combination
evaluation of the transparency committee
Rituximab

---
https://www.has-sante.fr/jcms/p_3428419/fr/teysuno-gimeracil/tegafur/oteracil-cancer-colorectal
2023
false
false
false
France
tegafur-gimeracil-oteracil
treatment outcome
insurance, health, reimbursement
adult
antineoplastic combined chemotherapy protocols
tegafur, combinations
neoplasm metastasis
antineoplastic agents
drug combinations
tegafur
gimeracil
oxonic acid
evaluation of the transparency committee
colorectal neoplasms

---
https://www.has-sante.fr/jcms/p_3433922/fr/talzenna-talazoparib-cancer-de-la-prostate
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
evaluation of the transparency committee

---
https://www.oncobretagne.fr/2023/05/prise-en-charge-en-ville-de-patients-atteints-de-cancer-synthese-regionale/
2023
France
scientific and technical information
disease
Cancer
neoplasms
cancer
fracture fixation
neoplasm, malignant
case management
has patient

---
https://www.has-sante.fr/jcms/p_3434604/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique
2023
false
false
false
France
evaluation of the transparency committee
zanubrutinib
leukemia, lymphoid
leukaemia
zanubrutinib
Brukinsa
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
chronic lymphocytic leukemia

---
https://www.has-sante.fr/jcms/p_3434157/fr/orgovyx-relugolix-cancer-de-la-prostate-avance-hormonodependant
2023
false
false
false
France
orgovyx
neoplasms, hormone-dependent
treatment outcome
insurance, health, reimbursement
advanced hormone-dependent prostate cancer
adult
Product containing precisely relugolix 120 milligram/1 each conventional release oral tablet (clinical drug)
administration, oral
relugolix
androgen antagonists
evaluation of the transparency committee
relugolix
prostatic neoplasms

---
https://www.has-sante.fr/jcms/p_3434163/fr/lonquex-lipegfilgrastim-facteur-de-croissance-granulocytaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
lipegfilgrastim
adult
child
adolescent
Chemotherapy-Induced febrile neutropenia
Chemotherapy-Induced febrile neutropenia
evaluation of the transparency committee
granulocyte colony-stimulating factor
lipegfilgrastim

---
http://nuxeo.edel.univ-poitiers.fr/nuxeo/site/esupversions/dda32ff9-7ea7-43de-9b76-dfa1836a68e4
2023
France
Physicians
activir
aged
case management
disease
has patient
patient care
role
activator appliances
principal
physician's role
medicine
physicians
hematology
primary health care
physicians, primary care
antineoplastic agents
Hematology

---
https://dumas.ccsd.cnrs.fr/dumas-04069207
2023
France
screening for cancer
emigration and immigration
prostate cancer
prostatism, nos
Records
prostate, nos
Literature
review literature as topic
prostatic neoplasms
early detection of cancer
cancer screening
consumer health information
readability
comprehension
Prostate cancer
malignant neoplasm prostate
patient given information

---
https://www.has-sante.fr/jcms/p_3442969/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
2023
false
false
false
France
selpercatinib
adult
adolescent
thyroid cancer, medullary
administration, oral
RET Inhibitor
antineoplastic agents
guidelines for drug use
advanced RET fusion-positive thyroid cancer
RET Fusion Positive
evaluation of the transparency committee
selpercatinib
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3443283/fr/pluvicto-lutecium-177lu-vipivotide-tetraxetan-cancer-de-la-prostate
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
radiopharmaceuticals
Lutetium Lu 177 Vipivotide Tetraxetan
lutetium (177Lu) vipivotide tetraxetan
adult
neoplasm metastasis
metastatic castration resistant prostate cancer
evaluation of the transparency committee
prostatic neoplasms, Castration-Resistant
lutetium

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-13-04-2023-sur-le-medicament-talzenna-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
administration, oral
talazoparib
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
adult
antineoplastic combined chemotherapy protocols
enzalutamide
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
metastatic castration resistant prostate cancer

---
https://ansm.sante.fr/tableau-acces-derogatoire/talazoparib-0-25-mg-gelule
2023
false
false
false
France
French
talazoparib
drug information

---
https://www.has-sante.fr/jcms/p_3442461/fr/xalkori-crizotinib-tumeurs-myofibroblastiques-inflammatoires-tmi
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Crizotinib
crizotinib
Inflammatory Myofibroblastic Tumor
antineoplastic agents
protein kinase inhibitors
child
adolescent
Childhood Inflammatory Myofibroblastic Tumor
soft tissue neoplasms
ALK Positive
administration, oral

---
https://www.cochrane.org/fr/CD012515/BREASTCA_formation-des-agents-de-sante-lexamen-des-seins-pour-la-detection-precoce-du-cancer-du-sein-dans-les
2023
United Kingdom
review of literature
french abstract
health education
asthenia
breast neoplasms
health
breast
detective
Breast cancer
breast cancer
early detection of cancer
examination of breast, nos
neoplasm, malignant
income

---
https://www.fondation-arc.org/sites/default/files/2023-01/Livre_R%C3%A9volutions_pdf_web.pdf
2023
France
popular works
Researches
neoplasms
cancer
Cancer
neoplasm, malignant
research

---
https://www.has-sante.fr/jcms/p_3444067/fr/kimmtrak-tebentafusp-melanome-de-l-uvee
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
Metastatic Uveal Melanoma
adult
uveal melanoma
Unresectable Uveal Melanoma
tebentafusp
HLA-A*02:01 antigen
HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive
evaluation of the transparency committee
melanoma
uveal neoplasms
tebentafusp

---
https://www.has-sante.fr/jcms/p_3444041/fr/verzenios-abemaciclib-cancer-du-sein-precoce-rh-/her2
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic agents
protein kinase inhibitors
abemaciclib
antineoplastic combined chemotherapy protocols
Adjuvant Therapy
Hormone Receptor-Positive Breast Carcinoma
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence
adult
evaluation of the transparency committee
abemaciclib
breast neoplasms

---
https://ansm.sante.fr/dossiers-thematiques/vaccins-contre-les-infections-a-papillomavirus-humains-hpv
2023
false
false
false
France
French
drug information
papillomavirus vaccines
papillomavirus infections
vaccine potency
papillomavirus vaccines
france
papillomavirus vaccines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ivosidenib
ivosidenib
ivosidenib
orphan drug production
antineoplastic agents
antineoplastic agents
adult
enzyme inhibitors
enzyme inhibitors
antineoplastic combined chemotherapy protocols
Azacitidine/Ivosidenib Regimen
leukemia, myeloid, acute
IDH1 NP_005887.2:p.R132X
leukemia, myeloid, acute
IDH1 Gene Mutation
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
mutation
administration, oral
IDH1 protein, human
IDH1 inhibitor
product surveillance, postmarketing
drug interactions
fertility
pregnancy
breast feeding
drug evaluation, preclinical
acute myeloid leukaemia with an IDH1 R132 mutation
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation

---
https://www.ema.europa.eu/en/medicines/human/EPAR/akeega
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
europe
Abiraterone Acetate/Niraparib
Abiraterone Acetate/Niraparib
Abiraterone Acetate
Abiraterone Acetate
niraparib
niraparib
antineoplastic agents
antineoplastic agents
neoplasm metastasis
prostatic neoplasms, Castration-Resistant
metastatic castration resistant prostate cancer
prostatic neoplasms, Castration-Resistant
adult
drug therapy, combination
prednisone
BRCA1 Gene Mutation
BRCA2 Gene Mutation
administration, oral
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Poly (ADP-Ribose) Polymerase-1
PARP2 protein, human
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Enzyme Inhibitors
steroid 17-alpha-hydroxylase
drug interactions
fertility
pregnancy
breast feeding
niraparib and abiraterone
drug evaluation, preclinical
metastatic castration-resistant prostate cancer and BRCA 1/2 mutations in whom chemotherapy is not clinically indicated

---
https://dares.travail-emploi.gouv.fr/publication/les-expositions-des-salaries-aux-produits-chimiques-cancerogenes
2023
France
journal article
carcinogens
carcinogen, nos
effects of exposure to external cause, nos
Exhibition

---
https://dares.travail-emploi.gouv.fr/publication/zoom-sur-les-expositions-4-produits-chimiques-cancerogenes
2023
France
scientific and technical information
carcinogen, nos
Exhibition
exposure to
carcinogens

---
https://www.has-sante.fr/jcms/p_3444785/fr/xalkori-crizotinib-lymphome-anaplasique-a-grandes-cellules-lagc
2023
false
false
false
France
French
treatment outcome
child
insurance, health, reimbursement
administration, oral
Crizotinib
crizotinib
evaluation of the transparency committee
adolescent
Refractory Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
antineoplastic agents
protein kinase inhibitors
lymphoma, large-cell, anaplastic

---
https://www.has-sante.fr/jcms/p_3444788/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible
2023
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
trastuzumab deruxtecan
trastuzumab deruxtecan
Antineoplastic Agents, Immunological
breast neoplasms
neoplasm metastasis
Metastatic HER2-Low Breast Carcinoma
adult
Unresectable Breast Carcinoma
HER2/Neu Low Expression
infusions, intravenous

---
https://www.cbip.be/fr/articles/4098?folia=4095
2023
false
false
false
Belgium
French
journal article
Immunosuppression Therapy
immunosuppressive agents
neoplasms
graft rejection
organ transplantation
risk
risk assessment
neoplasms

---
https://ansm.sante.fr/informations-de-securite/gavreto-pralsetinib-augmentation-du-risque-de-tuberculose-et-mesures-de-reduction-du-risque-associees
2023
false
false
false
France
French
pharmacovigilance note
risk
tuberculosis
pralsetinib
pralsetinib

---
https://kce.fgov.be/fr/publications/tous-les-rapports/health-technology-assessment-depistage-du-cancer-colorectal-connaissances-scientifiques-actuelles-et
2023
Belgium
technical report
early detection of cancer
Colorectal cancer
cancer screening
knowledge
screening for cancer
Colorectal Cancer
belgium
insight, nos
acquaintance
malignant neoplasm colon/rectum
colorectal neoplasms

---
https://publications.msss.gouv.qc.ca/msss/document-003597/
2023
Canada
public health guidelines
disease
infectious disease, nos
COVID-19
disease of respiratory system, nos
medical oncology
Drives
Diseases
health planning guidelines
medical futility
disease transmission, infectious
infectious diseases
Disease
communicable diseases

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Prevention-et-gestion-des-effets-indesirables-des-anticancereux-Hormonotherapies-dans-le-traitement-adjuvant-des-cancers-du-sein
2023
France
guidelines for drug use
Antineoplastic agents
adjuvant, nos
antineoplastic agents
hormonotherapy
breast

---
https://ansm.sante.fr/tableau-acces-derogatoire/enfortumab-vedotin-padcev
2023
false
false
false
France
French
drug information
insurance, health, reimbursement
enfortumab vedotin
enfortumab vedotin
Locally Advanced Urothelial Carcinoma
carcinoma, transitional cell
urologic neoplasms
Metastatic Urothelial Carcinoma
neoplasm metastasis
Refractory Urothelial Carcinoma
infusions, intravenous
antineoplastic agents

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/J-ai-un-cancer-comprendre-et-etre-aide-L-essentiel-format-accessible
2023
France
patient education handout
training support
neoplasms
neoplasm, malignant
cancer
Cancer

---
https://www.has-sante.fr/jcms/p_3404153/fr/kisqali-ribociclib-cancer-du-sein
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
antineoplastic agents
protein kinase inhibitors
ribociclib
antineoplastic combined chemotherapy protocols
Letrozole
Letrozole/Ribociclib Regimen
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
neoplasm metastasis
evaluation of the transparency committee
breast cancer
ribociclib
breast neoplasms

---
https://www.ema.europa.eu/en/medicines/human/EPAR/locametz
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Gozetotide
Gozetotide
drug approval
europe
Positron-Emission tomography
diagnostic uses of chemicals
gallium 68 PSMA-11
prostatic neoplasms
adult
gallium radioisotopes
radiopharmaceuticals
injections, intravenous
FOLH1 protein, human
gallium (68Ga) gozetotide
product surveillance, postmarketing
Radiopharmaceutical Preparation Kit Dosage Form
pregnancy
breast feeding

---
https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
radiopharmaceuticals
Lutetium Lu 177 Vipivotide Tetraxetan
Lutetium Lu 177 Vipivotide Tetraxetan
lutetium (177Lu) vipivotide tetraxetan
radiopharmaceuticals
radiopharmaceuticals
Lutetium-177
prostatic neoplasms, Castration-Resistant
neoplasm metastasis
PSMA-Positive Tumor
antineoplastic combined chemotherapy protocols
injections, intravenous
infusions, intravenous
FOLH1 protein, human
product surveillance, postmarketing
pregnancy
breast feeding

---
https://www.has-sante.fr/jcms/p_3406124/fr/tecentriq-atezolizumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
evaluation of the transparency committee
Tecentriq
neoplasm, malignant
"u" lymphocyte
cancer
atezolizumab
due to
Cancer
atezolizumab
bronchus, nos
Cell
carcinoma, non-small-cell lung
cells

---
https://www.has-sante.fr/jcms/p_3407460/fr/scemblix-asciminib-leucemie-myeloide-chronique
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
asciminib
leukemia, myelogenous, chronic, bcr-abl positive
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
recurrence
T315I mutation
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
antineoplastic agents
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://www.has-sante.fr/jcms/p_3407522/fr/yescarta-axicabtagene-ciloleucel-lymphome-folliculaire
2023
false
false
false
France
lymphoma, follicular
treatment outcome
insurance, health, reimbursement
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
infusions, intravenous
axicabtagene ciloleucel
evaluation of the transparency committee
axicabtagene ciloleucel

---
https://www.has-sante.fr/jcms/p_3407525/fr/enbrel-etanercept-immunosuppresseur
2023
false
false
false
France
insurance, health, reimbursement
evaluation of the transparency committee
immunosuppressive agents
Etanercept

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Barometre-cancer-2021-Rapport-planches
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Barometre-cancer-2021-Synthese
2023
France
technical report
research report
cancer
neoplasms
neoplasm, malignant
Cancer
albumin/globulin ratio

---
https://onco-occitanie.fr/
2023
false
true
false
France
French
community networks
medical oncology
association of health professionals

---
https://www.cbip.be/fr/articles/4004?folia=4002
2023
false
false
false
Belgium
French
primary prevention
vitamins
neoplasms
cardiovascular diseases
journal article
Evidence-Based medicine

---
https://www.ssmg.be/wp-content/uploads/RMG/396/RMG396_06-10.pdf
2023
France
journal article
neoplasms
exercise
Cancer
physics
cancer
Physics
neoplasm, malignant

---
https://nctcr.lu/fr/
Luxembourg
establishment, institution, organization
Researches
neoplasm, malignant
Cancer
central
translational research
Translational Research, Biomedical
academies and institutes
cancer
neoplasms

---
https://www.oncobretagne.fr/2023/02/livret-des-structures-de-coordination-en-cancerologie/
2023
France
scientific and technical information
formularies as topic
Handbook
Structure
medical oncology
coordination, nos

---
https://www.has-sante.fr/jcms/p_3411344/fr/lynparza-olaparib-cancer-du-sein-precoce-a-haut-risque-her2-negatif
2023
false
false
false
France
Early Stage HER2-Negative Breast Carcinoma
HER2/Neu Negative
High Risk Breast Carcinoma
breast neoplasms
mutation
treatment outcome
insurance, health, reimbursement
Germline BRCA1 Gene Mutation
Germline BRCA2 Gene Mutation
administration, oral
olaparib
evaluation of the transparency committee
olaparib
breast neoplasms
risk

---
https://www.has-sante.fr/jcms/p_3412130/fr/kimmtrak-tebentafusp-melanome-de-l-uvee
2023
false
false
false
France
uveal neoplasms
uveal melanoma
treatment outcome
insurance, health, reimbursement
tebentafusp
Unresectable Uveal Melanoma
Metastatic Uveal Melanoma
adult
infusions, intravenous
HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive
evaluation of the transparency committee
melanoma
tebentafusp

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Rapport-scientifique-2021-Les-actions-de-recherche-en-cancerologie
2023
France
technical report
action research
albumin/globulin ratio
research report
health services research
medical oncology
Scientific research

---
https://www.has-sante.fr/jcms/p_3412892/fr/retsevmo-selpercatinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
advanced RET fusion-positive non-small cell lung cancer
adult
RET Fusion Positive
administration, oral
antineoplastic agents
RET Inhibitor
selpercatinib
evaluation of the transparency committee
selpercatinib
carcinoma, non-small-cell lung

---
https://recalls-rappels.canada.ca/fr/avis-rappel/zejula-niraparib-mise-jour-sur-traitement-entretien-deuxieme-intention-ou-ulterieur
2023
false
false
false
Canada
French
English
drug information
niraparib

---
https://www.inspq.qc.ca/publications/3292
2023
Canada
technical report
breast cancer
screening for cancer
Program
controlled by
early detection of cancer
cancer screening
due to
receptors, proteinase-activated
Breast cancer
Benin
breast neoplasms
benin

---
https://www.has-sante.fr/jcms/p_3411128/fr/tedopi-her2-neu-cea-p53-mage-2-mage-3-cbnpc
2023
false
false
false
France
cancer vaccines
HLA-A2 antigen
Multi-neo-epitope Vaccine OSE 2101
evaluation of the transparency committee
carcinoma, non-small-cell lung

---
https://apps.who.int/iris/handle/10665/365789
https://www.who.int/fr/publications-detail/9789240067134
2023
false
false
false
Switzerland
public health guidelines
french abstract
orientation
breast neoplasms
neoplasm, malignant
orientation, nos
Breast cancer
evaluation studies as topic
detective
patient care management
amplifiers, electronic
Reinforcement, Psychology
reinforcement, nos
breast cancer
early detection of cancer

---
https://ansm.sante.fr/tableau-acces-derogatoire/tafasitamab-200-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
infusions, intravenous
tafasitamab
tafasitamab
drug information
adult
lymphoma, large B-Cell, diffuse

---
https://www.cochrane.org/fr/CD012974/SKIN_quels-sont-les-benefices-et-les-risques-du-traitement-neoadjuvant-traitement-medicamenteux-avant
2023
United Kingdom
review of literature
french abstract
kidnapping
risks and benefits
skin neoplasms
Tumors
malignant neoplasm of skin
neoplasms
Skin cancer
Tumors
Tumors
cancer of skin
Tumors
drug therapy
neoplasm, malignant
Tumors
Tumors
operative procedure, nos
Tumors
Tumors
Tumors
Tumors
Tumors
procedural approach, nos
surgical procedures, operative
drug, nos
Melanoma
crime
Tumors
risk assessment
melanoma
melanoma, cutaneous malignant
neoadjuvant therapy

---
https://www.cochrane.org/fr/CD013782/SYMPT_quels-sont-les-benefices-et-les-risques-de-lutilisation-de-corticosteroides-dans-le-traitement-de-la
2023
United Kingdom
review of literature
french abstract
risk assessment
neoplasms
fatigue
adrenal cortical hormone, nos
risks and benefits
cancer
neoplasm, malignant
Cancer
due to
adrenal cortex hormones
corticosteroid therapy
fatigue

---
https://www.has-sante.fr/jcms/p_3418105/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
sacituzumab govitecan
antineoplastic agents
Unresectable Hormone Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
adult
neoplasm metastasis
Metastatic Hormone Receptor-Positive Breast Carcinoma
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan

---
https://www.has-sante.fr/jcms/p_3395770/fr/keytruda-pembrolizumab-melanome-de-stade-iib-iic-ou-iii
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
adolescent
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIC Cutaneous Melanoma AJCC v6 and v7
melanoma
Stage III Cutaneous Melanoma AJCC v7
Advanced Cutaneous Melanoma
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
melanoma
pembrolizumab

---
https://www.has-sante.fr/jcms/p_3454298/fr/brukinsa-zanubrutinib-lymphome-de-la-zone-marginale-lzm
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
zanubrutinib
zanubrutinib
administration, oral
adult
Recurrent Marginal Zone Lymphoma
antineoplastic agents
protein kinase inhibitors

---
https://www.has-sante.fr/jcms/p_3455287/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
sacituzumab govitecan
sacituzumab govitecan
triple negative breast neoplasms
insurance, health, reimbursement
Unresectable Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
neoplasm metastasis
antineoplastic agents

---
https://www.has-sante.fr/jcms/p_3456506/fr/zejula-niraparib-cancer-de-l-ovaire
2023
false
false
false
France
niraparib
treatment outcome
insurance, health, reimbursement
administration, oral
tablets
Carcinoma, Ovarian Epithelial
advanced primary peritoneal cancer
fallopian tube neoplasms
peritoneal neoplasms
high grade serous epithelial ovarian cancer
Serous Tubal Intraepithelial Carcinoma
Recurrent Platinum-Sensitive Primary Peritoneal Carcinoma
evaluation of the transparency committee
niraparib

---
https://www.has-sante.fr/jcms/p_3456524/fr/sutent-sunitinib-tumeur-neuroendocrine-du-pancreas-pnet
2023
false
false
false
France
Unresectable Pancreatic Neuroendocrine Neoplasm
Metastatic Pancreatic Neuroendocrine Tumor
treatment outcome
insurance, health, reimbursement
protein kinase inhibitors
sunitinib
disease progression
adult
administration, oral
evaluation of the transparency committee
pancreatic neoplasms
neuroendocrine tumors
Sunitinib

---
https://www.inrs.fr/media.html?refINRS=NT%20108
2023
France
journal article
France
mutagens
french
France
carcinogens
France
France
france

---
https://www.inrs.fr/media.html?refINRS=TM%2075
2023
France
journal article
carcinogens
Allergy
hypersensitivity reaction, nos
adolescent
hypersensitivity

---
https://www.santepubliquefrance.fr/regions/antilles/documents/enquetes-etudes/2023/evaluation-de-la-performance-du-programme-de-depistage-organise-du-cancer-du-sein-resultats-et-evolution-des-indicateurs-de-performance-dans-les
2023
France
technical report
indication of
breast neoplasms
suggestive of
Organization
screening for cancer
early detection of cancer
Outcome Assessment, Health Care
breast cancer
resulting in
cancer screening
Organization
organization
program evaluation
Breast cancer
mass screening
oceans and seas
outcome measures
Regions

---
https://www.rst-sante-travail.fr/rst/pages-article/ArticleRST.html?ref=RST.TM%2075
2023
France
journal article
hypersensitivity
hypersensitivity reaction, nos
Allergy
carcinogens
adolescent

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Support-pedagogique-en-Facile-a-lire-et-a-comprendre-FALC-sur-le-depistage-du-cancer-colorectal-24-pages-A4
2023
France
patient education handout
instruction
support, nos
malignant neoplasm colon/rectum
colorectal neoplasms
Colorectal cancer
screening for cancer
early detection of cancer
teaching
cancer screening
Colorectal Cancer

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Support-pedagogique-en-Facile-a-lire-et-a-comprendre-FALC-sur-le-depistage-du-cancer-du-col-de-l-uterus-24-pages-A4
2023
France
patient education handout
teaching
screening for cancer
cancer screening
instruction
Cervical cancer
early detection of cancer
malignant neoplasm cervix
uterine cervical neoplasms
cancer of the uterine cervix
support, nos

---
https://www.has-sante.fr/jcms/p_3458293/fr/enhertu-trastuzumab-deruxtecan-cancer-de-l-estomac
2023
false
false
false
France
stomach neoplasms
adenocarcinoma
adult
treatment outcome
insurance, health, reimbursement
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Refractory Gastroesophageal Junction Adenocarcinoma
Refractory Gastric Adenocarcinoma
Advanced Gastric Adenocarcinoma
Antineoplastic Agents, Immunological
trastuzumab deruxtecan
evaluation of the transparency committee
trastuzumab deruxtecan

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Proposition-d-evolution-des-criteres-d-agrement-des-etablissements-de-sante-pour-le-traitement-du-cancer
2023
France
technical report
neoplasms
Cancer
cancer
proposita
accreditation
health facilities
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3459834/fr/imfinzi-/-tremelimumab-astrazeneca-durvalumab-/-tremelimumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
platinum compounds
antineoplastic combined chemotherapy protocols
Antineoplastic Agents, Immunological
bronchial neoplasms
neoplasm metastasis
Metastatic Lung Non-Small Cell Carcinoma
Activating EGFR Gene Mutation Negative
Activating ALK Gene Mutation Negative
Durvalumab/Tremelimumab Regimen
evaluation of the transparency committee
tremelimumab
carcinoma, non-small-cell lung
durvalumab

---
https://www.has-sante.fr/jcms/p_3460521/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
guidelines for drug use
nivolumab
infusions, intravenous
Antineoplastic Agents, Immunological
bronchial neoplasms
programmed cell death 1 receptor
antineoplastic combined chemotherapy protocols
PD-L1 Expression Greater than or Equal to 1 Percent
neoadjuvant therapy
adult
platinum compounds
Sensitizing EGFR Mutation Negative
ALK Gene Translocation Negative
evaluation of the transparency committee
Nivolumab
carcinoma, non-small-cell lung

---
https://www.irdes.fr/recherche/2023/qes-281-obstacles-ressources-et-contrastes-dans-les-parcours-de-soins-complexes.html
2023
France
journal article
psyche, nos
Cancer
snacks
mental disorders
persons
resources
critical pathways
health resources
neoplasms
nursing
severe
cancer
neoplasm, malignant

---
https://dumas.ccsd.cnrs.fr/dumas-04135563
2023
France
dissertations, academic
Pharmaceutical Dosage Form
Tool
Scientific Equipment
EDQM-HC Pharmaceutical Dosage Form Terminology
tool, nos
Oncology
Creation
Oncologists
Oncologist
Training
Used Quit Cigarette Smoking Videos
Reviewing
CDISC SDTM Pharmaceutical Dosage Form Terminology
Maintenance Clinical Trial Setting
interview
patient education as topic
Creation

---
https://www.minerva-ebp.be/FR/Analysis/832
2023
Belgium
critical appraisal or critical reading
Nonclinical Randomization
choice behavior
Localized Malignant Neoplasm
case study
malignant neoplasm prostate
Locally Advanced Malignant Neoplasm
prostatic neoplasms
Cancer Risk
prostate cancer
survival
general surgery
neoplasm, malignant
International Prognostic Index Low Risk Group
American College of Cardiology/American Heart Association Lesion Complexity Score A
resulting in
Long-Term
Prostate Cancer Outcomes Study
radiotherapy
Drug Accumulation 1.2 to 1.99
asthenia
activir
Similarity
Patient Observation
operative procedure, nos
snacks
watchful waiting
Case Series
risk
sampling studies
Case Study
IPSS-R Risk Category Low
radiation therapy, nos
Low Risk
outcome studies
Therapeutic Skin Surgery
X-ray Therapy
prostate, nos
Disease Risk Index Low Risk
Choose
Cancer Survivorship Research
therapeutics

---
https://www.has-sante.fr/jcms/p_3461359/fr/libtayo-cemiplimab-carcinome-epidermoide-cutane-metastatique-ou-localement-avance-cecm-ou-cecla
2023
false
false
false
France
skin neoplasms
treatment outcome
insurance, health, reimbursement
Metastatic Skin Squamous Cell Carcinoma
Locally Advanced Skin Squamous Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
evaluation of the transparency committee
cemiplimab
carcinoma, squamous cell

---
https://www.has-sante.fr/jcms/p_3461141/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Loss of Chromosome 17p
TP53 Gene Mutation
adult
del(17p) Negative
TP53 Gene Mutation Negative
Refractory Chronic Lymphocytic Leukemia
administration, oral
zanubrutinib
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
zanubrutinib
leukemia, lymphocytic, chronic, B-Cell

---
https://www.oecd-ilibrary.org/social-issues-migration-health/profils-sur-le-cancer-par-pays-france-2023_1dd7dd7f-fr;jsessionid=pQ5uYkR-c191So4VCBnQxjiqsQouiY6Ts9pm8xb0.ip-10-240-5-38
2023
France
technical report
Country Code
neoplasms
Profile
neoplasm, malignant
france
french
cancer
Netherlands
CDISC SEND Country Terminology
CHFR Gene
Malignant Neoplasm

---
https://ansm.sante.fr/tableau-marr/lisocabtagene-maraleucel
2023
false
false
false
France
French
guidelines for drug use
risk management
Lisocabtagene Maraleucel
Lisocabtagene Maraleucel
Product containing only lisocabtagene maraleucel in parenteral dose form (medicinal product form)
Cytokine Release Syndrome
continuity of patient care
gene therapy
immunotherapy, adoptive
signs and symptoms
nervous system diseases
patients guideline
lisocabtagene maraleucel

---
https://www.has-sante.fr/jcms/p_3463592/fr/breyanzi-lisocabtagene-maraleucel-lymphome-folliculaire-de-grade-3b-lf3b
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
lymphoma, large B-Cell, diffuse
High Grade B-Cell Lymphoma
adult
Primary Mediastinal Large B-Cell Lymphoma
immunotherapy, adoptive
gene therapy
infusions, intravenous
evaluation of the transparency committee
Grade 3b Follicular Lymphoma
Lisocabtagene Maraleucel
lymphoma, follicular

---
https://www.has-sante.fr/jcms/p_3463441/fr/tecvayli-teclistamab-myelome-multiple
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Triple-Class Refractory Multiple Myeloma
Recurrent Multiple Myeloma
adult
Antineoplastic Agents, Immunological
bispecific monoclonal antibodies
teclistamab
evaluation of the transparency committee
multiple myeloma
Teclistamab

---
https://www.who.int/fr/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer
2023
Switzerland
scientific and technical information
popular works
cancer
neoplasms
Human Papillomavirus Viruses
viral disease other/nos
neoplasm, malignant
human papillomavirus, nos
Human Papillomavirus-Related Malignant Neoplasm
Human Papillomavirus Infection
papillomaviridae
infectious disease, nos
papillomavirus infections

---
https://ansm.sante.fr/actualites/campagne-de-vaccination-contre-les-virus-hpv-lansm-deploie-un-dispositif-de-surveillance-renforcee
2023
false
false
false
France
French
drug information
mass vaccination
papillomavirus vaccines
france
papillomavirus infections
pharmacovigilance
product surveillance, postmarketing
papillomavirus vaccines

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/La-reunion-de-concertation-pluridisciplinaire-en-cancerologie
2023
France
guideline
Reunion
medical oncology
interdisciplinary medical team conference, nos
group processes
cooperative behavior
Meeting

---
Summary Safety Review - Keytruda (pembrolizumab) and Tecentriq (atezolizumab) - Assessing the Potential Risk of Aplastic Anemia
https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1691503886633
2023
false
false
false
Canada
French
drug evaluation
Drug-Related side effects and adverse reactions
pembrolizumab
antibodies, monoclonal, humanized
atezolizumab
Antineoplastic Agents, Immunological
risk assessment
anemia, aplastic
Immune Checkpoint Inhibitors
canada
pharmacovigilance note

---
https://www.has-sante.fr/jcms/p_3466095/fr/jemperli-dostarlimab-cancer-de-l-endometre
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
platinum compounds
evaluation of the transparency committee
Advanced Endometrial Carcinoma
dostarlimab
endometrial neoplasms

---
https://ansm.sante.fr/informations-de-securite/blenrep-belantamab-mafodotin-et-myelome-multiple-lema-recommande-de-ne-pas-renouveler-son-amm-conditionnelle-en-raison-dun-manque-de-preuve-defficacite
2023
false
false
false
France
French
drug information
treatment outcome
belantamab mafodotin

---
https://www.has-sante.fr/jcms/p_3450915/fr/lumykras-sotorasib-cancer-du-poumon
2023
false
false
false
France
evaluation of the transparency committee
sotorasib
Sotorasib
Lung Carcinoma
lung neoplasms
lung cancer
neoplasm, malignant
sotorasib

---
https://www.has-sante.fr/jcms/p_3465836/fr/breyanzi-lisocabtagene-maraleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-lymphome-de-haut-grade-a-cellules-b-lhgcb-lymphome-mediastinal-primitif-a-grandes-cellules-b-lmpgcb-et-lymphome-folliculaire-de-grade-3b-lf3b
2023
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
lymphoma, large B-Cell, diffuse
lymphoma, follicular
mediastinal neoplasms
Grade 3b Follicular Lymphoma
Primary Mediastinal Large B-Cell Lymphoma
High Grade B-Cell Lymphoma
Antineoplastic Agents, Immunological
Lisocabtagene Maraleucel
gene therapy
adult
infusions, intravenous
lisocabtagene maraleucel

---
https://ansm.sante.fr/tableau-marr/epcoritamab
2023
false
false
false
France
French
risk management
bispecific monoclonal antibodies
Epcoritamab
patients guideline
Cytokine Release Syndrome
signs and symptoms
Immune Effector Cell Associated Neurotoxicity Syndrome
cell-associated neurotoxicity
drug information
epcoritamab

---
https://journals.openedition.org/activites/8703
2023
France
journal article
Prevention Study
Exhibition
chemical compound, nos
learning, nos
Antineoplastic Agent
Chemical Exposure
New Lesion Identification
protestantism
Medication
Preventive Intervention
Version
effects of exposure to external cause, nos
Biospecimen Collection Method
Supplies
drug, nos
learning
antineoplastic agents
Newar Language
Learning
GDC Therapeutic Agent Terminology

---
Nous contacter.
28/04/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.